Nøkkelinformasjon info chevron_right

Viktig informasjon i saken hentes i sanntid direkte fra EPO sitt register (European Patent Register), slik at du enkelt og raskt får oversikt i saken.
Beskrivelse Verdi
Saken / databasen er sist oppdatert info  
Tittel SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS
Status
Hovedstatus
Detaljstatus 		I kraft info EP patent gjort gjeldende i Norge EP patent besluttet gjeldende i Norge
Patentnummer NO/EP3057964
Europeisk (EP) publiserings nummer EP3057964
EP levert
EP søknadsnummer 14790937.8
EP meddelt
Prioritet 2013.10.14, US 201361890718 P
Sakstype Europeisk
Løpedag
Utløpsdato
Allment tilgjengelig
Validert i Norge
Innehaver Eisai R&D Management Co., Ltd. (JP)
Oppfinner HAWKINS, Lynn (US) .... se mer/flere nedenfor
Fullmektig ZACCO NORWAY AS (NO)
Lenke til European patent Register Informasjon i saken, dokumenter og patentfamilie
Patentfamilie Se i Espacenet

Sammendrag og figur info chevron_right

EPO translation logo


Se forsidefigur og sammendrag i Espacenet

Beskrivelse og krav info chevron_right

T3

Beskrivelse

Krav

Patentkrav1. Forbindelse med formel (I) eller farmasøytisk akseptabelt salt derav:eller en stereoisomer derav eller blanding av stereoisomerer derav,hvori minst én av R1 og R2 er -H, metyl eller etyl, og den andre er-H; eller den andre erC1-C6alkyl som eventuelt er substituert med:-OH, metoksy, etoksy, -OCH(CH3)2, -O(CH2)2CH3, fenyl, furanyl, -O(CH2)2OH, fenoksy, metyltio, -F, -N(CH3)2, cyano, pyridinyloksy, fluorfenoksy, isokromanyl, fenol, benzylamino, -NHCH3, okso-, amino, karboksyl, 7-leddet spiroaminyl, et tre- til seksleddet sykloalkyl, mettet eller umettet og som eventuelt inkluderer ett eller flere heteroatomer valgt fra O og N, og eventuelt substituert ved ett eller flere C- eller N-atomer med metyl, cyano, fluor, metylamino eller trifluormetyl; eller den andre er C3-C7sykloalkan, mettet eller umettet, eventuelt brodannet, som eventuelt inkluderer ett eller flere heteroatomer valgt fra O, S og N, og eventuelt substituert ved ett eller flere C- eller N-atomer med metyl, etyl, pyridinyl, azetidinyl, acetamidyl, karboksamidyl, cyano, fluor, metylamino eller trifluormetyl; ellerR1 og R2, sammen med nitrogenatomet som de er bundet til, danner et 8- til 11-leddet spirodiamin, et 8-leddet bisyklodiamin, et 7-leddet spiroksamin, et piperidinyl eventuelt substituert med etyl, eller et fire- til seksleddet sykloalkyl, eventuelt substituert med minst ett av karboksamidyl, aminometyl, metyl, (etylamino)metyl, (dimetylamino)metyl, dimetylamino, (metylamino)metyl og amino; og hvoriR3 er -H eller metyl.2. Forbindelsen med formel 1 eller farmasøytisk akseptabelt salt derav, hvori forbindelsen eller saltet har en stereokjemisk konfigurasjon valgt fra én av de som er vist i gruppen som består av formel (Ia), formel (Ib), formel (Ic) og formel (Id): 3. Forbindelsen ifølge krav 1, valgt fra gruppen som består av:(2R,6R)-4-(8-cyanokinolin-5-yl)-N-etyl-6-metylmorfolin-2-karboksamid; (2R,6R)-4-(8-cyanokinolin-5-yl)-N-isopropyl-6-metylmorfolin-2-karboksamid; (6R)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-karboksamid; 5-((2R,6R)-2-((S)-3-etylpiperazin-1-karbonyl)-6-metylmorfolino)kinolin-8-karbonitril; (2R,6R)-4-(8-cyanokinolin-5-yl)-N-(3,4-difluorbenzyl)-6-metylmorfolin-2-karboksamid; 5-((2R,6R)-2-((S)-3-aminopyrrolidine-1-karbonyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2R,6R)-2-(azetidin-1-karbonyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2R,6R)-2-([1,4'-bipiperidin]-1'-karbonyl)-6-metylmorfolino)kinolin-8-karbonitril; (2R,6R)-4-(8-cyanokinolin-5-yl)-N-syklopropyl-6-metylmorfolin-2-karboksamid;5-((2R,6R)-2-(3-aminoazetidin-1-karbonyl)-6-metylmorfolino)kinolin-8-karbonitril;(2R,6R)-4-(8-cyanokinolin-5-yl)-N-(2-hydroksyetyl)-6-metylmorfolin-2-karboksamid; (2R,6R)-4-(8-cyanokinolin-5-yl)-N-(2-metoksyetyl)-6-metylmorfolin-2-karboksamid; (2R,6R)-4-(8-cyanokinolin-5-yl)-N-((R)-2-hydroksypropyl)-6-metylmorfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-N-((S)-1-hydroksypropan-2-yl)-6-metylmorfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-N-((R)-1-hydroksypropan-2-yl)-6-metylmorfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-N-((S)-1-hydroksybutan-2-yl)-6-metylmorfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-N-((S)-1-hydroksy-3-metylbutan-2-yl)-6-metylmorfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-N-((S)-2-hydroksy-1-fenyletyl)-6-metylmorfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-N-((R)-2-hydroksy-1-fenyletyl)-6-metylmorfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-N-(2-hydroksybutyl)-6-metylmorfolin-2-karboksamid; (2R,6R)-4-(8-cyanokinolin-5-yl)-N-(2-etoksyetyl)-6-metylmorfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-N-((R)-1-hydroksybutan-2-yl)-6-metylmorfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-N-(1,3-dihydroksypropan-2-yl)-6-metylmorfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-N-(2,3-dihydroksypropyl)-6-metylmorfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-6-metyl-N-(((R)-tetrahydrofuran-2-yl)metyl)morfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-6-metyl-N-((tetrahydrofuran-2-yl)metyl)morfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-6-metyl-N-(2-propoksyetyl)morfolin-2-karboksamid; (2R,6R)-4-(8-cyanokinolin-5-yl)-N-((R)-1-hydroksypentan-2-yl)-6-metylmorfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-N-(2-isopropoksyetyl)-6-metylmorfolin-2-karboksamid; (2R,6R)-4-(8-cyanokinolin-5-yl)-N-(1-metoksybutan-2-yl)-6-metylmorfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-N-(2-(2-fluorfenyl)-2-hydroksyetyl)-6-metylmorfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-N-((R)-1-hydroksy-3-metylbutan-2-yl)-6-metylmorfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-N-(2,2-dimetoksyetyl)-6-metylmorfolin-2-karboksamid; (2R,6R)-4-(8-cyanokinolin-5-yl)-N-(2-(2-hydroksyetoksy)etyl)-6-metylmorfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-N-((1S,2S)-2-hydroksysykloheksyl)-6-metylmorfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-N-(2-hydroksysykloheksyl)-6-metylmorfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-N-(1-hydroksyheksan-2-yl)-6-metylmorfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-N-((S)-1-hydroksy-3,3-dimetylbutan-2-yl)-6-metylmorfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-N-((S)-1-hydroksyheksan-2-yl)-6-metylmorfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-N-((2S,3S)-1-hydroksy-3-metylpentan-2-yl)-6-metylmorfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-N-((S)-1-hydroksy-4-metylpentan-2-yl)-6-metylmorfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-N-((R)-1-hydroksy-4-metylpentan-2-yl)-6-metylmorfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-6-metyl-N-((4-metylmorfolin-2-yl)metyl)morfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-N-((S)-1-hydroksy-4-(metyltio)butan-2-yl)-6-metylmorfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-6-metyl-N-(2-fenoksyetyl)morfolin-2-karboksamid; (2R,6R)-4-(8-cyanokinolin-5-yl)-N-((S)-1-hydroksy-3-fenylpropan-2-yl)-6-metylmorfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-6-metyl-N-(2-fenoksypropyl)morfolin-2-karboksamid; (2R,6R)-4-(8-cyanokinolin-5-yl)-N-(2-hydroksy-3-fenylpropyl)-6-metylmorfolin-2-karboksamid; (2R,6R)-4-(8-cyanokinolin-5-yl)-6-metyl-N-(2-(pyridin-3-yloksy)propyl)morfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-N-(2-(4-fluorfenoksy)etyl)-6-metylmorfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-N-(2-(3-fluorfenyl)-2-hydroksyetyl)-6-metylmorfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-N-((S)-1-sykloheksyl-3-hydroksypropan-2-yl)-6-metylmorfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-N-(isokroman-1-ylmetyl)-6-metylmorfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-N-(2-hydroksy-3-fenoksypropyl)-6-metylmorfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-N-((1S,2R)-1-hydroksy-1-(4-hydroksyfenyl)propan-2-yl)-6-metylmorfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-N-((1S)-1,3-dihydroksy-1-fenylpropan-2-yl)-6-metylmorfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-N-(2-hydroksy-3-(piperazin-1-yl)propyl)-6-metylmorfolin-2-karboksamid;(2R,6R)-N-(azetidin-3-yl)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-6-metyl-N-((S)-pyrrolidin-3-yl)morfolin-2-karboksamid; (2R,6R)-4-(8-cyanokinolin-5-yl)-6-metyl-N-((R)-pyrrolidin-3-yl)morfolin-2-karboksamid; (2R,6R)-4-(8-cyanokinolin-5-yl)-6-metyl-N-((S)-piperidin-3-yl)morfolin-2-karboksamid; (2R,6R)-4-(8-cyanokinolin-5-yl)-6-metyl-N-((R)-piperidin-3-yl)morfolin-2-karboksamid; (2R,6R)-4-(8-cyanokinolin-5-yl)-6-metyl-N-((S)-pyrrolidin-2-ylmetyl)morfolin-2-karboksamid;(2R,6R)-N-(2-(benzylamino)etyl)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-6-metyl-N-(pyridin-2-yl)morfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-6-metyl-N-(6-metylpyridin-2-yl)morfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-6-metyl-N-(5-metylisoksazol-3-yl)morfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-6-metyl-N-(2,2,2-trifluoretyl)morfolin-2-karboksamid; (2R,6R)-4-(8-cyanokinolin-5-yl)-N-(2,2-difluoretyl)-6-metylmorfolin-2-karboksamid; (2R,6R)-4-(8-cyanokinolin-5-yl)-6-metyl-N-(3,3,3-trifluorpropyl)morfolin-2-karboksamid; (2R,6R)-4-(8-cyanokinolin-5-yl)-N-(2-(dimetylamino)-2-metylpropyl)-6-metylmorfolin-2-karboksamid; (2R,6R)-4-(8-cyanokinolin-5-yl)-6-metyl-N-((S)-morfolin-2-ylmetyl)morfolin-2-karboksamid;(2R,6R)-4-(8-cynokinolin-5-yl)-6-metyl-N-(((S)-4-metylmorfolin-2-yl)metyl)morfolin-2-karboksamid-eddiksyreacetat;(2R,6R)-4-(8-cyanokinolin-5-yl)-N-(2-fluoretyl)-6-metylmorfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-N-(3-fluorpropyl)-6-metylmorfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-6-metyl-N-((S)-1,1,1-trifluorpropan-2-yl)morfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-6-metyl-N-((R)-1,1,1-trifluorpropan-2-yl)morfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-N-(1,3-dimetyl-1H-pyrazol-5-yl)-6-metylmorfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-6-metyl-N-(1-metyl-1H-pyrazol-5-yl)morfolin-2-karboksamid;(2R,6R)-N-(cyanometyl)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-karboksamid;(2R,6R)-N-(1-cyanosyklopropyl)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-6-metyl-N-(1,2,4-tiadiazol-5-yl)morfolin-2-karboksamid; (2R,6R)-4-(8-cyanokinolin-5-yl)-6-metyl-N-(3-metyl-1,2,4-tiadiazol-5-yl)morfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-6-metyl-N-(piperidin-4-yl)morfolin-2-karboksamid;5-((2R,6R)-2-metyl-6-(2,6-diazaspiro[3.4]oktan-2-karbonyl)morfolino)kinolin-8-karbonitril;5-((2R,6R)-2-metyl-6-(3-((metylamino)metyl)azetidin-1-karbonyl)morfolino)kinolin-8-karbonitril;(2R,6R)-4-(8-cyanokinolin-5-yl)-N-((4-fluorpiperidin-4-yl)metyl)-6-metylmorfolin-2-karboksamid;(2R,6R)-N-(azetidin-3-ylmetyl)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-karboksamid; 5-((2R,6R)-2-metyl-6-(2,6-diazaspiro[3.5]nonan-2-karbonyl)morfolino)kinolin-8-karbonitril;5-((2R,6R)-2-metyl-6-(1,6-diazaspiro[3.4]oktan-1-karbonyl)morfolino)kinolin-8-karbonitril;5-((2R,6R)-2-metyl-6-(1,7-diazaspiro[4.4]nonan-7-karbonyl)morfolino)kinolin-8-karbonitril;(2R,6R)-N-(3-karbamoyl-1-metyl-1H-pyrazol-4-yl)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-6-metyl-N-(oksetan-3-ylmetyl)morfolin-2-karboksamid; (2R,6R)-4-(8-cyanokinolin-5-yl)-6-metyl-N-(tetrahydro-2H-pyran-4-yl)morfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-6-metyl-N-(tetrahydrofuran-3-yl)morfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-6-metyl-N-((3-metyloksetan-3-yl)metyl)morfolin-2-karboksamid;5-((2R,6R)-2-metyl-6-(2-oksa-6-azaspiro[3.3]heptan-6-karbonyl)morfolino)kinolin-8-karbonitril;(2R,6R)-4-(8-cyanokinolin-5-yl)-6-metyl-N-(oksetan-3-yl)morfolin-2-karboksamid; (2R,6R)-N-((3-(aminometyl)oksetan-3-yl)metyl)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-6-metyl-N-(oksetan-2-ylmetyl)morfolin-2-karboksamid; 5-((2R,6R)-2-metyl-6-(piperazin-1-karbonyl)morfolino)kinolin-8-karbonitril;(2R,6R)-4-(8-cyanokinolin-5-yl)-6-metyl-N-(2-(metylamino)etyl)morfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-6-metyl-N-((S)-3,3,3-trifluor-2-hydroksypropyl)morfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-6-metyl-N-((R)-3,3,3-trifluor-2-hydroksypropyl)morfolin-2-karboksamid;Metyl-2-((2R,6R)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-karboksamido)acetat;(2R,6R)-4-(8-cyanokinolin-5-yl)-N-(2-(dimetylamino)etyl)-6-metylmorfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-6-metyl-N-((S)-4,4,4-trifluor-3-hydroksybutyl)morfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-6-metyl-N-((R)-4,4,4-trifluor-3-hydroksybutyl)morfolin-2-karboksamid;(2R,6R)-N-(3-amino-4,4,4-trifluorbutyl)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-karboksamid;2-((2R,6R)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-karboksamido)eddiksyre;1-((2R,6R)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-karbonyl)azetidin-3-karboksamid; 5-((2R,6R)-2-metyl-6-(2,7-diazaspiro[4.4]nonan-2-karbonyl)morfolino)kinolin-8-karbonitril;5-((2R,6R)-2-metyl-6-(3,9-diazaspiro[5.5]undekan-3-karbonyl)morfolino)kinolin-8-karbonitril;(2R,6R)-N-(3-karbamoylpyridin-4-yl)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-6-metyl-N-((R)-morfolin-2-ylmetyl)morfolin-2-karboksamid; (2R,6R)-4-(8-cyanokinolin-5-yl)-6-metyl-N-(pyridin-4-yl)morfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-6-metyl-N-(pyridin-3-yl)morfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-6-metyl-N-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)morfolin-2-karboksamid;(2R,6R)-N-(1-(azetidin-3-yl)-1H-pyrazol-4-yl)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-karboksamid;(2R,6R)-N-((1H-pyrazol-5-yl)metyl)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-karboksamid;(2R,6R)-N-((1H-pyrazol-4-yl)metyl)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-6-metyl-N-((3-(trifluormetyl)pyridin-2-yl)metyl)morfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-6-metyl-N-(1-(pyridin-2-yl)etyl)morfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-6-metyl-N-(pyridin-2-ylmetyl)morfolin-2-karboksamid; (2R,6R)-4-(8-cyanokinolin-5-yl)-6-metyl-N-((6-metylpyridin-2-yl)metyl)morfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-6-metyl-N-((1-metylpiperidin-2-yl)metyl)morfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-6-metyl-N-((3-metylpyridin-2-yl)metyl)morfolin-2-karboksamid;(2R,6R)-N-(4-cyano-1H-pyrazol-3-yl)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-N-((3S,4R)-4-fluor-1-metylpyrrolidin-3-yl)-6-metylmorfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-N-((3S,4R)-4-fluorpiperidin-3-yl)-N,6-dimetylmorfolin-2-karboksamid;5-((2R,6R)-2-(3-(aminometyl)azetidin-1-karbonyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2R,6R)-2-(3-((etylamino)metyl)azetidin-1-karbonyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2R,6R)-2-(3-((dimetylamino)metyl)azetidin-1-karbonyl)-6-metylmorfolino)kinolin-8-karbonitril;(2R,6R)-4-(8-cyanokinolin-5-yl)-6-metyl-N-(1-metylazepan-4-yl)morfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-6-metyl-N-(((2R,6R)-6-metylmorfolin-2-yl)metyl)morfolin-2-karboksamid; 5-((2R,6R)-2-metyl-6-(oktahydropyrrolo[3,4-c]pyrrol-2-karbonyl)morfolino)kinolin-8-karbonitril;(2R,6R)-4-(8-cyanokinolin-5-yl)-6-metyl-N-((R)-pyrrolidin-2-ylmetyl)morfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-6-metyl-N-((S)-piperidin-2-ylmetyl)morfolin-2-karboksamid;(2R,6R)-N-((1R,3R,5S)-8-azabisyklo[3.2.1]oktan-3-yl)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-karboksamid;(2R,6R)-N-(azepan-4-yl)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-karboksamid;(2R,6R)-N-((1R,5S,6S)-3-azabisyklo[3.1.0]heksan-6-yl)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-N-6-dimetylmorfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-N-(((2S,6R)-4,6-dimetylmorfolin-2-yl)metyl)-6-metylmorfolin-2-karboksamid;5-((2R,6R)-2-(4-(dimetylamino)piperidin-1-karbonyl)-6-metylmorfolino)kinolin-8-karbonitril;(2R,6R)-4-(8-cyanokinolin-5-yl)-6-metyl-N-(1-metylpiperidin-4-yl)morfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-N-((3S,4R)-4-fluorpyrrolidin-3-yl)-6-metylmorfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-N-((3S,4R)-4-fluorpiperidin-3-yl)-6-metylmorfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-6-metyl-N-(2-azaspiro[3.3]heptan-6-yl)morfolin-2-karboksamid;(2R,6R)-N-(1-(2-amino-2-oksoetyl)piperidin-4-yl)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-karboksamid;5-((2R,6R)-2-(4-aminopiperidin-1-karbonyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2R,6R)-2-(4-amino-4-metylpiperidin-1-karbonyl)-6-metylmorfolino)kinolin-8-karbonitril;(2R,6R)-4-(8-cyanokinolin-5-yl)-N,6-dimetyl-N-((R)-piperidin-3-yl)morfolin-2-karboksamid;(2R,6R)-N-(2-karbamoylpyridin-4-yl)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-N-6-dimetyl-N-((S)-piperidin-3-yl)morfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-N-(1-etylpiperidin-4-yl)-6-metylmorfolin-2-karboksamid; (2R,6R)-4-(8-cyanokinolin-5-yl)-N-(1-etylpiperidin-3-yl)-6-metylmorfolin-2-karboksamid; (2R,6R)-4-(8-cyanokinolin-5-yl)-6-metyl-N-((R)-1-metylpiperidin-3-yl)morfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-6-metyl-N-(4-metylpiperidin-4-yl)morfolin-2-karboksamid;(2R,6R)-N-(2-amino-2-metylpropyl)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-karboksamid;rel-(2R,6R)-4-(8-cyanokinolin-5-yl)-N-((3R,4S)-4-fluorpyrrolidin-3-yl)-6-metylmorfolin-2-karboksamid;rel-(2R,6R)-4-(8-cyanokinolin-5-yl)-N-((3S,4R)-4-fluorpyrrolidin-3-yl)-6-metylmorfolin-2-karboksamid;(2R,6R)-N-(azepan-3-yl)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-6-metyl-N-(1-metylazepan-3-yl)morfolin-2-karboksamid;(2R,6R)-4-(8-cyanokinolin-5-yl)-N-(1,4-dimetylpiperidin-4-yl)-6-metylmorfolin-2-karboksamid; og(2R,6R)-4-(8-cyanokinolin-5-yl)-N-(4-fluor-1-metylpiperidin-3-yl)-6-metylmorfolin-2-karboksamid;eller et farmasøytisk akseptabelt salt derav.4. Forbindelsen ifølge krav 3 eller farmasøytisk akseptabelt salt derav, hvori forbindelsen eller saltet velges fra gruppen som består av rel-(2R,6R)-4-(8-cyanokinolin-5-yl)-N-((3R,4S)-4-fluorpyrrolidin-3-yl)-6-metylmorfolin-2-karboksamidhydroklorid og (2R,6R)-4-(8-cyanokinolin-5-yl)-6-metyl-N-(1-metylpiperidin-4-yl)morfolin-2-karboksamid.5. Forbindelse med formel (I) ifølge krav 1, som er (2R, 6R)-4-(8-cyanokinolin-5-yl)-N-[(3S,4R)-4-fluorpyrrolidin-3-yl]-6-metylmorfolin-2-karboksamid eller et farmasøytisk akseptabelt salt derav.6. Farmasøytisk akseptabelt salt ifølge krav 5, som er (2R,6R)-4-(8-cyanokinolin-5-yl)-N-((3S,4R)-4-fluorpyrrolidin-3-yl)-6-metylmorfolin-2-karboksamidhydroklorid.7. Forbindelse med formel (II) eller farmasøytisk akseptabelt salt derav:hvori R4 er -H eller metyl;R5 er C1-C5alkyl som er mettet, delvis mettet eller umettet, og som eventuelt er substituert med:-H, -Cl, -F, -OH, -NH2, okso-, -N(CH2CH3)2, fenyl, sykloheksyl, fenyltriazolyl, sykloheksyltriazolyl, pyridinyl, pyrrolidinyl,morfolinyl eventuelt substituert med metyl eller hydroksymetyl,-O-, substituert med:C1-C6alkyl, metylfenyl, metylsykloheksyl, pyridinyl, diazinyl eller fenyl, eventuelt substituert med -F eller metyl,-NH-, substituert med:C2-C7alkyl som er lineært, forgrenet eller syklisk, mettet eller umettet, og eventuelt substituert med okso-, fenyl, metyl eller -OH,pyridinyl eventuelt substituert med metyl, metoksy, fenyl eller amino,diazinyl eventuelt substituert med etyl,benzoimidazolyl, metylfenyl, fenylpyrazolyl, naftyridyl,fenyl eventuelt substituert med -F, metyl, etyl eller etoksy,imidazolidinyl eventuelt substituert med metyleller R5 erhvori n er 1-3, og hvori det sykliske aminet eventuelt er substituert medC1-C3alkyl eventuelt substituert med-OH, -F, fenyl, -NH2, sykloheksyl, -N(CH3)2, -C(O)NH2, metylsulfonamidyl, benzensulfonamidyl, metylbenzensulfonamidyl ellerpyrrolidinyl eventuelt substituert med metyl eller hydroksyl eller-NHC(O)R6, hvori R6 erC1-C5alkyl, fenyl, pyridinyl, fluorfenyl, metylsulfonyl, fluorbenzensulfonyl, dimetylpyrazolsulfonyl ellerpyrazolyl eventuelt substituert med metyl;piperidinyl eventuelt substituert med -C(O)CH3, -C(O)CH2CH3, metyl, okso-, C(O)Ph, -NH2, -NH-C(O)CH3 ellerpiperazinyl eventuelt substituert med -C(O)OC(CH3)3, metyl, -C(O)CH3, -C(O)Ph, C(O)CH(CH3)2, -C(O)CH3 eller metylsulfonyl; ellerR5 erder n er 1 eller 2, og hvori det sykliske diaminet eventuelt er substituert på minst ett karbonatom medmetyl, okso-, -N(CH3)2, amino, -CH2CH3 ellerpiperidinyl eventuelt substituert med metyl, -C(O)CH3, -C(O)CH(CH3)2, -C(O)Ph eller -C(O)OC(CH3)3 oghvori R7 er -H, fenyl, -C(O)CH3, C1-C3alkyl, -C(O)NH2 eller -C(O)Ph; ogR8 er metoksy eller cyano,eller en forbindelse eller farmasøytisk akseptabelt salt derav, valgt fra gruppen som består av:5-((2S,6R)-2-([1,4'-bipiperidin]-1'-ylmetyl)-6-metylmorfolino)kinolin-8-karbonitril, 5-((2R,7R)-2-(hydroksymetyl)-7-metyl-1,4-oksazepan-4-yl)kinolin-8-karbonitril, 5-((2S,7R)-2-([1,4'-bipiperidin]-1'-ylmetyl)-7-metyl-1,4-oksazepan-4-yl)kinolin-8-karbonitril,5-((2R,6S)-2,6-dietylmorfolino)kinolin-8-karbonitril, og5-((2R,6R)-2-((benzyloksy)metyl)-6-etylmorfolino)kinolin-8-karbonitril.8. Forbindelsen eller det farmasøytisk akseptable saltet derav ifølge krav 7, hvori forbindelsen er saltet velges fra gruppen som består av:5-((2R,6S)-2,6-dimetylmorfolino)kinolin-8-karbonitril;5-((2R,6S)-2,6-dimetylmorfolino)kinolin-8-karbonitrildihydroklorid;5-((2R,6S)-2,6-dimetylmorfolino)kinolin-8-karbonitrilmetansulfonat;5-((2R,6S)-2,6-dimetylmorfolino)kinolin-8-karbonitril-bis(2,2,2-trifluoracetat);5-((2R,6S)-2,6-dimetylmorfolino)kinolin-8-karbonitril-bis(sulfonat);5-((2R,6S)-2,6-dimetylmorfolino)kinolin-8-karbonitrilsulfonat;5-((2S,6R)-2,6-dimetylmorfolino)kinolin-8-karbonitril-2,3-dihydroksysuksinat;5-((2S,6R)-2,6-dimetylmorfolino)kinolin-8-karbonitrildimetansulfonat;5-(2-(klormetyl)morfolino)kinolin-8-karbonitril;(S)-5-(2-(klormetyl)morfolino)kinolin-8-karbonitril;N-(((2S,6R)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-yl)metyl)acetamid;N-(((2S,6R)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-yl)metyl)pivalamid;5-(2-metylmorfolino)kinolin-8-karbonitril; 5-((2S,6S)-2,6-dimetylmorfolino)kinolin-8-karbonitril;5-(2-etylmorfolino)kinolin-8-karbonitril;5-((2S,6R)-2-(aminometyl)-6-metylmorfolino)kinolin-8-karbonitril;5-(2-(hydroksymetyl)-6-metylmorfolino)kinolin-8-karbonitril;(2R,6S)-4-(8-metoksykinolin-5-yl)-2,6-dimetylmorfolin;5-((2R,6S)-2,6-dimetylmorfolino)kinolin-8-karboksamid;(R)-5-(2-metylmorfolino)kinolin-8-karbonitril;5-((2R,6R)-2-(hydroksymetyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2R,6R)-2-(metoksymetyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2R,6R)-2-((benzyloksy)metyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2R,6R)-2-(fluormetyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2R,6R)-2-(etoksymetyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2R,6R)-2-(isopropoksymetyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2R,6R)-2-(isobutoksymetyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2R,6R)-2-(klormetyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2R,6R)-2-((heksyloksy)metyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2R,6R)-2-((sykloheksylmetoksy)metyl)-6-metylmorfolino)kinolin-8-karbonitril; 5-((2R,6S)-2-metyl-6-propylmorfolino)kinolin-8-karbonitril;5-((2S,6S)-2-(fluormetyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2S,6S)-2-(klormetyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2R,6R)-2-((2,6-dimetylfenoksy)metyl)-6-metylmorfolino)kinolin-8-karbonitril; 5-((2R,6S)-2-metyl-6-pentylmorfolino)kinolin-8-karbonitril;5-((2R,6R)-2-formyl-6-metylmorfolino)kinolin-8-karbonitril;N-(((2S,6R)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-yl)metyl)-2-fenylpropanamid; 5-((2R,6R)-2-(1-hydroksyallyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2R,6R)-2-((S)-1-hydroksyallyl)-6-metylmorfolino)kinolin-8-karbonitril;N-(((2S,6R)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-yl)metyl)-1-fenylsyklobutankarboksamid;5-((2R,6R)-2-((R)-1-hydroksyallyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2R,6S)-2-metyl-6-(pyrrolidin-1-ylmetyl)morfolino)kinolin-8-karbonitril;5-((2S,6R)-2-((dietylamino)metyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2S,6R)-2-((benzylamino)metyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2R,6R)-2-metyl-6-(fenoksymetyl)morfolino)kinolin-8-karbonitril;5-((2R,6R)-2-metyl-6-((m-tolyloksy)metyl)morfolino)kinolin-8-karbonitril;5-((2R,6R)-2-metyl-6-((p-tolyloksy)metyl)morfolino)kinolin-8-karbonitril;5-((2R,6R)-2-(1-hydroksypropyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2R,6R)-2-((R)-1-hydroksypentyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2R,6R)-2-((S)-1-hydroksypentyl)-6-metylmorfolino)kinolin-8-karbonitril; 5-((2R,6R)-2-((R)-sykloheksyl(hydroksy)metyl)-6-metylmorfolino)kinolin-8-karbonitril; 5-((2R,6R)-2-((S)-sykloheksyl(hydroksy)metyl)-6-metylmorfolino)kinolin-8-karbonitril; N-(((2S,6R)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-yl)metyl)-2-fenylacetamid; 5-((2R,6R)-2-((R)-1-hydroksy-2-fenyletyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2R,6R)-2-((S)-1-hydroksy-2-fenyletyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2R,6R)-2-((R)-1-hydroksy-3-fenylpropyl)-6-metylmorfolino)kinolin-8-karbonitril; 5-((2R,6R)-2-((S)-1-hydroksy-3-fenylpropyl)-6-metylmorfolino)kinolin-8-karbonitril; 5-((2R,6S)-2-metyl-6-((fenylamino)metyl)morfolino)kinolin-8-karbonitril;5-((2R,6S)-2-metyl-6-((m-tolylamino)metyl)morfolino)kinolin-8-karbonitril;5-((2R,6S)-2-metyl-6-((o-tolylamino)metyl)morfolino)kinolin-8-karbonitril;5-((2R,6S)-2-metyl-6-((p-tolylamino)metyl)morfolino)kinolin-8-karbonitril;5-((2R,6R)-2-((3,4-difluorfenoksy)metyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2R,6R)-2-((3-fluorfenoksy)metyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2S,6R)-2-(((1,2-dimetyl-1H-benzo[d]imidazol-5-yl)amino)metyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2S,6R)-2-(((1-etyl-2-metyl-1H-benzo[d]imidazol-5-yl)amino)metyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2S,6R)-2-((sykloheksylamino)metyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2R,6R)-2-((2-fluorfenoksy)metyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2R,6R)-2-metyl-6-propionylmorfolino)kinolin-8-karbonitril;5-((2R,6R)-2-(sykloheksankarbonyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2R,6R)-2-metyl-6-(3-fenylpropanoyl)morfolino)kinolin-8-karbonitril;5-((2R,6R)-2-metyl-6-((o-tolyloksy)metyl)morfolino)kinolin-8-karbonitril;5-((2R,6S)-2-metyl-6-((pyrimidin-2-ylamino)metyl)morfolino)kinolin-8-karbonitril;5-((2R,6S)-2-metyl-6-((pyridin-2-ylamino)metyl)morfolino)kinolin-8-karbonitril;5-((2R,6S)-2-metyl-6-(((6-metylpyridin-2-yl)amino)metyl)morfolino)kinolin-8-karbonitril;5-((2R,6S)-2-metyl-6-(((5-metylpyridin-2-yl)amino)metyl)morfolino)kinolin-8-karbonitril;5-((2S,6R)-2-(((R)-2-(hydroksymetyl)pyrrolidin-1-yl)metyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2R,6R)-2-((2,2-dimetylpyrrolidin-1-yl)metyl)-6-metylmorfolino)kinolin-8-karbonitril; 5-((2S,6R)-2-((2-isopropylpyrrolidin-1-yl)metyl)-6-metylmorfolino)kinolin-8-karbonitril; 5-((2R,6S)-2-metyl-6-(((S)-2-metylpyrrolidin-1-yl)metyl)morfolino)kinolin-8-karbonitril; 5-((2R,6S)-2-metyl-6-(((S)-3-fenylpyrrolidin-1-yl)metyl)morfolino)kinolin-8-karbonitril; 5-((2R,6S)-2-metyl-6-(((R)-3-metylpyrrolidin-1-yl)metyl)morfolino)kinolin-8-karbonitril; 5-((2S,6R)-2-(((S)-3-hydroksypyrrolidin-1-yl)metyl)-6-metylmorfolino)kinolin-8-karbonitril; 5-((2R,6S)-2-metyl-6-(((4-metylpyridin-2-yl)amino)metyl)morfolino)kinolin-8-karbonitril;5-((2R,6S)-2-metyl-6-((3-fenylpyrrolidin-1-yl)metyl)morfolino)kinolin-8-karbonitril; 5-((2S,6R)-2-(((6-metoksypyridin-3-yl)amino)metyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2R,6S)-2-metyl-6-(((R)-2-metylpyrrolidin-1-yl)metyl)morfolino)kinolin-8-karbonitril; 5-((2S,6R)-2-((2,5-dimetylpyrrolidin-1-yl)metyl)-6-metylmorfolino)kinolin-8-karbonitril; 5-((2S,6R)-2-(((4-metoksypyridin-2-yl)amino)metyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2S,6R)-2-(((6-metoksypyridin-2-yl)amino)metyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2R,6S)-2-metyl-6-(((1-fenyl-1H-pyrazol-5-yl)amino)metyl)morfolino)kinolin-8-karbonitril;5-((2S,6R)-2-(((S)-2-(hydroksymetyl)pyrrolidin-1-yl)metyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2S,6R)-2-(((R)-3-hydroksypyrrolidin-1-yl)metyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2R,6S)-2-metyl-6-(((S)-3-metylpyrrolidin-1-yl)metyl)morfolino)kinolin-8-karbonitril; 5-((2S,6R)-2-((3,3-dimetylpyrrolidin-1-yl)metyl)-6-metylmorfolino)kinolin-8-karbonitril; 5-((2R,6R)-2-metyl-6-((R)-3-fenyl-1-(pyrrolidin-1-yl)propyl)morfolino)kinolin-8-karbonitril;5-((2R,6R)-2-metyl-6-((S)-3-fenyl-1-(pyrrolidin-1-yl)propyl)morfolino)kinolin-8-karbonitril;5-((2S,6R)-2-(((3-metoksypyridin-2-yl)amino)metyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2S,6R)-2-(((R)-3-hydroksypiperidin-1-yl)metyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2S,6R)-2-(((2R,6S)-2,6-dimetylpiperidin-1-yl)metyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2S,6R)-2-(((S)-3-hydroksypiperidin-1-yl)metyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2S,6R)-2-((4-hydroksypiperidin-1-yl)metyl)-6-metylmorfolino)kinolin-8-karbonitril; 5-((2S,6R)-2-((2-(hydroksymetyl)piperidin-1-yl)metyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2R,6S)-2-metyl-6-((2-metylpiperidin-1-yl)metyl)morfolino)kinolin-8-karbonitril; 5-((2S,6R)-2-((2-etylpiperidin-1-yl)metyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2S,6R)-2-((2,3-dimetylpiperazin-1-yl)metyl)-6-metylmorfolino)kinolin-8-karbonitril; 5-((2R,6S)-2-metyl-6-((pyridin-3-ylamino)metyl)morfolino)kinolin-8-karbonitril; 5-((2R,6S)-2-metyl-6-((pyridin-4-ylamino)metyl)morfolino)kinolin-8-karbonitril;5-((2R,6S)-2-metyl-6-(((S)-2-(trifluormetyl)pyrrolidin-1-yl)metyl)morfolino)kinolin-8-karbonitril;5-((2R,6S)-2-metyl-6-((4-metylpiperidin-1-yl)metyl)morfolino)kinolin-8-karbonitril; 5-((2S,6R)-2-((4,4-difluorpiperidin-1-yl)metyl)-6-metylmorfolino)kinolin-8-karbonitril; 5-((2R,6S)-2-metyl-6-((4-fenylpiperidin-1-yl)metyl)morfolino)kinolin-8-karbonitril;5-((2S,6R)-2-((4-fluorpiperidin-1-yl)metyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2S,6R)-2-((syklopentylamino)metyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2R,6S)-2-metyl-6-(((3-metylsykloheksyl)amino)metyl)morfolino)kinolin-8-karbonitril;5-((2R,6S)-2-metyl-6-(((3-metylpyridin-2-yl)amino)metyl)morfolino)kinolin-8-karbonitril;5-((2R,6R)-2-etyl-6-(hydroksymetyl)morfolino)kinolin-8-karbonitril;5-((2R,6S)-2-metyl-6-(((4-fenylpyridin-2-yl)amino)metyl)morfolino)kinolin-8-karbonitril; 5-((2R,6S)-2-metyl-6-(piperazin-1-ylmetyl)morfolino)kinolin-8-karbonitril;5-((2R,6S)-2-metyl-6-((4-fenylpiperazin-1-yl)metyl)morfolino)kinolin-8-karbonitril; 5-((2S,6R)-2-(((6-aminopyridin-2-yl)amino)metyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2S,6R)-2-((2,5-dimetylpiperazin-1-yl)metyl)-6-metylmorfolino)kinolin-8-karbonitril; 5-((2S,6R)-2-((4-acetylpiperazin-1-yl)metyl)-6-metylmorfolino)kinolin-8-karbonitril; 5-((2S,6R)-2-(((2S,4R)-4-hydroksy-2-(hydroksymetyl)pyrrolidin-1-yl)metyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2R,6S)-2-metyl-6-(((R)-2-metylpiperazin-1-yl)metyl)morfolino)kinolin-8-karbonitril; 5-((2R,6S)-2-metyl-6-(((R)-3-metylpiperazin-1-yl)metyl)morfolino)kinolin-8-karbonitril; 5-((2R,6S)-2-metyl-6-(((S)-3-metylpiperazin-1-yl)metyl)morfolino)kinolin-8-karbonitril; 5-((2S,6R)-2-(((2R,SR)-2,5-dimetylpiperazin-1-yl)metyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2S,6R)-2-(((2R,5S)-2,5-dimetylpiperazin-1-yl)metyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2R,6S)-2-metyl-6-(((4-metylsykloheksyl)amino)metyl)morfolino)kinolin-8-karbonitril;5-((2S,6R)-2-((syklobutylamino)metyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2S,6R)-2-((sykloheptylamino)metyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2S,6R)-2-(((4-hydroksysykloheksyl)amino)metyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2S,6R)-2-(((2-hydroksysyklopentyl)amino)metyl)-6-metylmorfolino)kinolin-8-karbonitril; 5-((2R,6S)-2-metyl-6-(((2-metylsykloheksyl)amino)metyl)morfolino)kinolin-8-karbonitril;5-((2R,6S)-2-metyl-6-(((5-fenylpyridin-2-yl)amino)metyl)morfolino)kinolin-8-karbonitril; 5-((2R,6S)-2-metyl-6-(((3-fenylpyridin-2-yl)amino)metyl)morfolino)kinolin-8-karbonitril; 5-((2S,6R)-2-((((1S,3R)-3-hydroksysyklopentyl)amino)metyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2S,6R)-2-(((3-etoksypyridin-2-yl)amino)metyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2R,6S)-2-metyl-6-(((2-fenylpyridin-4-yl)amino)metyl)morfolino)kinolin-8-karbonitril; 5-((2R,6S)-2-metyl-6-(((6-fenylpyridin-2-yl)amino)metyl)morfolino)kinolin-8-karbonitril; (S)-5-(2-((pyridin-2-ylamino)metyl)morfolino)kinolin-8-karbonitril;5-((2R,6S)-2-metyl-6-((2-metyl-5-oksopiperazin-1-yl)metyl)morfolino)kinolin-8-karbonitril;5-((2R,6S)-2-metyl-6-((4-metylpiperazin-1-yl)metyl)morfolino)kinolin-8-karbonitril; 5-((2R,6S)-2-metyl-6-((4-propylpiperazin-1-yl)metyl)morfolino)kinolin-8-karbonitril; 5-((2S,6R)-2-((4-(dimetylamino)piperidin-1-yl)metyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2S,6R)-2-([1,4'-bipiperidin]-1'-ylmetyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2S,6R)-2-([1,4'-bipiperidin]-1'-ylmetyl)-6-metylmorfolino)kinolin-8-karbonitrildihydroklorid;5-((2S,6R)-2-(((R)-3-aminopiperidin-1-yl)metyl)-6-metylmorfolino)kinolin-8-karbonitril; 5-((2S,6R)-2-((4-aminopiperidin-1-yl)metyl)-6-metylmorfolino)kinolin-8-karbonitril; 5-((2S,6R)-2-(((5-fluorpyrimidin-2-yl)amino)metyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2R,6S)-2-metyl-6-(piperidin-1-ylmetyl)morfolino)kinolin-8-karbonitril;5-((2R,6S)-2-metyl-6-(morfolinometyl)morfolino)kinolin-8-karbonitril;5-((2S,6R)-2-(((2S,6R)-2,6-dimetylmorfolino)metyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2S,6R)-2-(((2R,6R)-2-(hydroksymetyl)-6-metylmorfolino)metyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2R,6S)-2-metyl-6-((4-(pyridin-2-yl)piperazin-1-yl)metyl)morfolino)kinolin-8-karbonitril;5-((2R,6S)-2-metyl-6-((4-(pyridin-4-yl)piperazin-1-yl)metyl)morfolino)kinolin-8-karbonitril;N-(1-(((2S,6R)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-yl)metyl)piperidin-4-yl)acetamid;N-(1-(((2S,6R)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-yl)metyl)piperidin-4-yl)acetamidhydroklorid; 1-(((2S,6R)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-yl)metyl)piperidin-4-karboksamid;N-(1-(((2S,6R)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-yl)metyl)piperidin-4-yl)benzamid;5-((2S,6R)-2-((4-isopropylpiperazin-1-yl)metyl)-6-metylmorfolino)kinolin-8-karbonitril; 4-(((2S,6R)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-yl)metyl)piperazin-1-karboksamid;5-((2S,6R)-2-((4-sykloheksylpiperidin-1-yl)metyl)-6-metylmorfolino)kinolin-8-karbonitril; 5-((2R,6S)-2-metyl-6-((4-(pyrrolidin-1-yl)piperidin-1-yl)metyl)morfolino)kinolin-8-karbonitril;5-((2R,6R)-2-((4-sykloheksyl-1H-1,2,3-triazol-1-yl)metyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2R,6R)-2-metyl-6-((4-fenyl-1H-1,2,3-triazol-1-yl)metyl)morfolino)kinolin-8-karbonitril;5-((2R,6S)-2-metyl-6-((2-okso-[1,4'-bipiperidin]-1'-yl)metyl)morfolino)kinolin-8-karbonitril;5-((2S,6R)-2-(((5-etylpyrimidin-2-yl)amino)metyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2S,6R)-2-(((6-amino-3,5-dimetylpyridin-2-yl)amino)metyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2R,6S)-2-metyl-6-((pyrazin-2-ylamino)metyl)morfolino)kinolin-8-karbonitril;5-((2S,6R)-2-(((1,3-dimetyl-1H-pyrazol-5-yl)amino)metyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2S,6R)-2-((4-etylpiperazin-1-yl)metyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2R,6S)-2-metyl-6-((3-(pyrrolidin-1-yl)azetidin-1-yl)metyl)morfolino)kinolin-8-karbonitril;5-((2R,6S)-2-metyl-6-((3-(piperidin-1-yl)azetidin-1-yl)metyl)morfolino)kinolin-8-karbonitril;5-((2S,6R)-2-(((R)-2,4-dimetylpiperazin-1-yl)metyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2S,6R)-2-((4-(hydroksymetyl)piperidin-1-yl)metyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2S,6R)-2-((R)-[1,3'-bipyrrolidin]-1'-ylmetyl)-6-metylmorfolino)kinolin-8-karbonitril; 5-((2R,6S)-2-metyl-6-(((R)-3-(piperidin-1-yl)pyrrolidin-1-yl)metyl)morfolino)kinolin-8-karbonitril;5-((2R,6S)-2-metyl-6-((4-metyl-1,4-diazepan-1-yl)metyl)morfolino)kinolin-8-karbonitril; 5-((2S,6R)-2-((4-benzoylpiperazin-1-yl)metyl)-6-metylmorfolino)kinolin-8-karbonitril; N-(1-(((2S,6R)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-yl)metyl)piperidin-4-yl)nikotinamid;N-(1-(((2S,6R)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-yl)metyl)piperidin-4-yl)isonikotinamid;N-(1-(((2S,6R)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-yl)metyl)piperidin-4-yl)pikolinamid;N-(1-(((2S,6R)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-yl)metyl)piperidin-4-yl)heksanamid;N-(1-(((2S,6R)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-yl)metyl)piperidin-4-yl)isobutyramid;N-(1-(((2S,6R)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-yl)metyl)piperidin-4-yl)isobutyramidhydroklorid;N-(1-(((2S,6R)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-yl)metyl)piperidin-4-yl)pivalamid;5-((2R,6S)-2-metyl-6-((4-morfolinopiperidin-1-yl)metyl)morfolino)kinolin-8-karbonitril; tert-butyl-4-(1-(((2S,6R)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-yl)metyl)piperidin-4-yl)piperazin-1-karboksylat;tert-butyl-4-(4-(((2S,6R)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-yl)metyl)piperazin-1-yl)piperidin-1-karboksylat;5-((2R,6S)-2-metyl-6-((4-(piperazin-1-yl)piperidin-1-yl)metyl)morfolino)kinolin-8-karbonitril;5-((2R,6S)-2-metyl-6-((4-(piperidin-4-yl)piperazin-1-yl)metyl)morfolino)kinolin-8-karbonitril;5-((2R,6S)-2-metyl-6-((3-(4-metylpiperazin-1-yl)azetidin-1-yl)metyl)morfolino)kinolin-8-karbonitril;5-((2S,6R)-2-([4,4'-bipiperidin]-1-ylmetyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2S,6R)-2-((1'-acetyl-[4,4'-bipiperidin]-1-yl)metyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2R,6S)-2-metyl-6-((1'-metyl-[4,4'-bipiperidin]-1-yl)metyl)morfolino)kinolin-8-karbonitril;5-((2R,6S)-2-metyl-6-((3-(piperazin-1-yl)azetidin-1-yl)metyl)morfolino)kinolin-8-karbonitril;5-((2S,6R)-2-((3-(4-acetylpiperazin-1-yl)azetidin-1-yl)metyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2S,6R)-2-((1'-isobutyryl-[4,4'-bipiperidin]-1-yl)metyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2S,6R)-2-((3-(4-benzoylpiperazin-1-yl)azetidin-1-yl)metyl)-6-metylmorfolino)kinolin-8-karbonitril; 5-((2S,6R)-2-((1'-benzoyl-[4,4'-bipiperidin]-1-yl)metyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2R,6S)-2-metyl-6-((4-(1-metylpiperidin-4-yl)piperazin-1-yl)metyl)morfolino)kinolin-8-karbonitril;5-((2S,6R)-2-((4-(1-acetylpiperidin-4-yl)piperazin-1-yl)metyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2S,6R)-2-((4-(1-isobutyrylpiperidin-4-yl)piperazin-1-yl)metyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2S,6R)-2-((4-(1-benzoylpiperidin-4-yl)piperazin-1-yl)metyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2S,6R)-2-((3-(4-isobutyrylpiperazin-1-yl)azetidin-1-yl)metyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2S,6R)-2-((4-(4-acetylpiperazin-1-yl)piperidin-1-yl)metyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2S,6R)-2-((4-(4-isobutyrylpiperazin-1-yl)piperidin-1-yl)metyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2S,6R)-2-((4-(4-benzoylpiperazin-1-yl)piperidin-1-yl)metyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2R,6S)-2-metyl-6-((4-(4-metylpiperazin-1-yl)piperidin-1-yl)metyl)morfolino)kinolin-8-karbonitril;5-((2R,6S)-2-metyl-6-((4-(4-metylpiperazin-1-yl)piperidin-1-yl)metyl)morfolino)kinolin-8-karbonitriltrihydroklorid;5-((2S,6R)-2-([1,4'-bipiperidin]-1'-ylmetyl)-6-metylmorfolino)-2-metylkinolin-8-karbonitril;N-((R)-1-(((2S,6R)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-yl)metyl)pyrrolidin-3-yl)acetamid;N-((R)-1-(((2S,6R)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-yl)metyl)pyrrolidin-3-yl)isobutyramid;5-((2R,6S)-2-metyl-6-(((S)-3-(piperidin-1-yl)pyrrolidin-1-yl)metyl)morfolino)kinolin-8-karbonitril;5-((2R,6S)-2-metyl-6-(((S)-3-(piperidin-1-yl)pyrrolidin-1-yl)metyl)morfolino)kinolin-8-karbonitrildihydroklorid;5-((2R,6S)-2-metyl-6-((3-morfolinoazetidin-1-yl)metyl)morfolino)kinolin-8-karbonitril; 5-((2R,6S)-2-metyl-6-((3-((S)-2-metylpyrrolidin-1-yl)azetidin-1-yl)metyl)morfolino)kinolin-8-karbonitril;5-((2R,6S)-2-metyl-6-(((S)-2-metylpiperazin-1-yl)metyl)morfolino)kinolin-8-karbonitril; 5-((2S,6R)-2-(((S)-2,4-dimetylpiperazin-1-yl)metyl)-6-metylmorfolino)kinolin-8-karbonitril; 5-((2S,6R)-2-(((R)-3,4-dimetylpiperazin-1-yl)metyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2S,6R)-2-(((S)-3,4-dimetylpiperazin-1-yl)metyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2S,6R)-2-(((S)-3-etylpiperazin-1-yl)metyl)-6-metylmorfolino)kinolin-8-karbonitril; 5-((2S,6R)-2-(((S)-3-etylpiperazin-1-yl)metyl)-6-metylmorfolino)kinolin-8-karbonitrildihydroklorid;5-((2S,6R)-2-(((S)-3-etyl-4-metylpiperazin-1-yl)metyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2S,6R)-2-((4-(azepan-1-yl)piperidin-1-yl)metyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2S,6R)-2-((S)-[1,3'-bipyrrolidin]-1'-ylmetyl)-6-metylmorfolino)kinolin-8-karbonitril; 5-((2S,6R)-2-((3-(4-aminopiperidin-1-yl)azetidin-1-yl)metyl)-6-metylmorfolino)kinolin-8-karbonitril;N-(1-(1-(((2S,6R)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-yl)metyl)azetidin-3-yl)piperidin-4-yl)acetamid;5-((2R,6S)-2-metyl-6-((3-(4-(metylsulfonyl)piperazin-1-yl)azetidin-1-yl)metyl)morfolino)kinolin-8-karbonitril;5-((2S,6R)-2-((3-((S)-3-hydroksypyrrolidin-1-yl)azetidin-1-yl)metyl)-6-metylmorfolino)kinolin-8-karbonitril;N-(1-(((2S,6R)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-yl)metyl)piperidin-4-yl)-1,3-dimetyl-1H-pyrazol-4-karboksamid;N-(1-(1-(((2S,6R)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-yl)metyl)azetidin-3-yl)piperidin-4-yl)-1,3-dimetyl-1H-pyrazol-4-karboksamid;N-(1-(((2S,6R)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-yl)metyl)piperidin-4-yl)metansulfonamid;N-(1-(((2S,6R)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-yl)metyl)piperidin-4-yl)benzensulfonamid;N-(1-(((2S,6R)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-yl)metyl)piperidin-4-yl)-4-fluorbenzensulfonamid;5-((2S,6R)-2-((3-aminoazetidin-1-yl)metyl)-6-metylmorfolino)kinolin-8-karbonitril;N-(1-(((2S,6R)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-yl)metyl)azetidin-3-yl)acetamid;N-(1-(((2S,6R)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-yl)metyl)azetidin-3-yl)-4-fluorbenzamid;N-(1-(((2S,6R)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-yl)metyl)azetidin-3-yl)metansulfonamid; N-(1-(((2S,6R)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-yl)metyl)azetidin-3-yl)-4-fluorbenzensulfonamid;N-(1-(((2S,6R)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-yl)metyl)azetidin-3-yl)-1,3-dimetyl-1H-pyrazol-4-sulfonamid;N-(1-(((2S,6R)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-yl)metyl)piperidin-4-yl)-1,3-dimetyl-1H-pyrazol-4-sulfonamid;N-(1-(((2S,6R)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-yl)metyl)azetidin-3-yl)isobutyramid;5-((2R,6S)-2-metyl-6-(((S)-2-metyl-5-oksopiperazin-1-yl)metyl)morfolino)kinolin-8-karbonitril;5-((2R,6S)-2-metyl-6-(((R)-2-metyl-5-oksopiperazin-1-yl)metyl)morfolino)kinolin-8-karbonitril;5-((2R,6S)-2-metyl-6-(((R)-2-metyl-3-oksopiperazin-1-yl)metyl)morfolino)kinolin-8-karbonitril;5-((2R,6S)-2-metyl-6-(((S)-2-metyl-3-oksopiperazin-1-yl)metyl)morfolino)kinolin-8-karbonitril;5-((2R,6S)-2-metyl-6-((2,4,5-trimetylpiperazin-1-yl)metyl)morfolino)kinolin-8-karbonitril;5-((2R,6S)-2-metyl-6-((2,3,4-trimetylpiperazin-1-yl)metyl)morfolino)kinolin-8-karbonitril;N-((R)-1-(((2S,6R)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-yl)metyl)pyrrolidin-3-yl)benzamid;5-((2S,6R)-2-(((R)-3-(dimetylamino)pyrrolidin-1-yl)metyl)-6-metylmorfolino)kinolin-8-karbonitril;N-((S)-1-(((2S,6R)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-yl)metyl)pyrrolidin-3-yl)acetamid;N-((S)-1-(((2S,6R)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-yl)metyl)pyrrolidin-3-yl)isobutyramid;N-((S)-1-(((2S,6R)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-yl)metyl)pyrrolidin-3-yl)benzamid;5-((2S,6R)-2-(((S)-3-(dimetylamino)pyrrolidin-1-yl)metyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2R,6R)-2-metyl-6-((pyrazin-2-yloksy)metyl)morfolino)kinolin-8-karbonitril;N-(1-(((2S,6R)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-yl)metyl)azetidin-3-yl)benzamid;5-((2S,6R)-2-((3,3-dimetylpiperazin-1-yl)metyl)-6-metylmorfolino)kinolin-8-karbonitrildihydroklorid; 5-((2R,6S)-2-metyl-6-((3,3,4-trimetylpiperazin-1-yl)metyl)morfolino)kinolin-8-karbonitrildihydroklorid;5-((2R,6R)-2-((R)-1-hydroksyetyl)-6-metylmorfolino)kinolin-8-karbonitril;1-(((2S,6R)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-yl)metyl)-N-etylpiperidin-4-karboksamid;1-(((2S,6R)-4-(8-cyanokinolin-5-yl)-6-metylmorfolin-2-yl)metyl)-N-etylpiperidin-4-karboksamidhydroklorid;5-((2R,6R)-2-((S)-1-hydroksyetyl)-6-metylmorfolino)kinolin-8-karbonitril;5-((2R,6R)-2-metyl-6-((pyridin-2-yloksy)metyl)morfolino)kinolin-8-karbonitril;5-((2R,6R)-2-metyl-6-((pyrimidin-2-yloksy)metyl)morfolino)kinolin-8-karbonitril;5-((2R,6R)-2-metyl-6-((R)-1-(pyrimidin-2-yloksy)etyl)morfolino)kinolin-8-karbonitril; 5-((2R,6R)-2-metyl-6-((S)-1-(pyrimidin-2-yloksy)etyl)morfolino)kinolin-8-karbonitril; og 5-((2R,6R)-2-((S)-hydroksy(pyridin-2-yl)metyl)-6-metylmorfolino)kinolin-8-karbonitril.9. Forbindelse med formel (III) eller farmasøytisk akseptabelt salt derav:hvoriR11 er H eller metyl;R10 er H eller, når både R11 og R9 er H, er metyl-1,4'-bipiperidinyl;R9 er -H eller er -CH2- substituert med 1,4'-bipiperidinyl, okso-, hydroksyl, metylpyridinyl eller piperidinyl eventuelt substituert med hydroksyl, -N(CH3)2 eller piperidinyl, eller en forbindelse eller farmasøytisk akseptabelt salt derav, valgt fra gruppen som består av 5-(3-(klormetyl)-5-metylfenyl)kinolin-8-karbonitril og 5-(3-metyl-5-((4-metylpiperazin-1-yl)metyl)fenyl)kinolin-8-karbonitril.10. Forbindelsen eller det farmasøytisk akseptable saltet derav ifølge krav 9, hvori forbindelsen er valgt fra gruppen som består av:5-(3-([1,4'-bipiperidin]-1'-ylmetyl)fenyl)kinolin-8-karbonitril;5-(4-([1,4'-bipiperidin]-1'-ylmetyl)fenyl)kinolin-8-karbonitril;5-(3-formyl-5-metylfenyl)kinolin-8-karbonitril;5-(3-(hydroksymetyl)-5-metylfenyl)kinolin-8-karbonitril; 5-(3-((4-hydroksypiperidin-1-yl)metyl)-5-metylfenyl)kinolin-8-karbonitril;5-(3-((4-(dimetylamino)piperidin-1-yl)metyl)-5-metylfenyl)kinolin-8-karbonitril; og5-(3-([1,4'-bipiperidin]-1'-ylmetyl)-5-metylfenyl)kinolin-8-karbonitril.11. Forbindelse eller farmasøytisk akseptabelt salt derav ifølge et hvilket som helst av kravene 1-10, for anvendelse ved behandling av en systematisk lupus erythematosus eller lupus.12. Farmasøytisk sammensetning omfattende minst én forbindelse eller farmasøytisk akseptabelt salt ifølge et hvilket som helst av kravene 1-10 og minst én farmasøytisk akseptabel bærer.13. Den farmasøytiske sammensetningen ifølge krav 12, hvori forbindelsen eller det farmasøytisk akseptable saltet derav har en IC50 mindre enn eller lik 100 nM mot humane TLR7-reseptorer i en HEK-293-cellelinje.14. Forbindelse eller farmasøytisk akseptabelt salt derav ifølge et hvilket som helst av kravene 1-10 for anvendelse ved behandling av en systematisk lupus erythematosus, kutan lupus, nevropsykiatrisk lupus eller lupus.
Hva betyr A1, B, B1, C osv? info

Klasser info chevron_right

Innehaver(e) info chevron_right

Innehaver i EP:
Eisai R&D Management Co., Ltd.
6-10, Koishikawa 4-chome Bunkyo-ku Tokyo 112-8088 JP

Oppfinner(e) info chevron_right

HAWKINS, Lynn
963 Lowell Road Concord, Massachusetts 01742 US
CARLSON, Eric
14 Blair Road Merrimack, New Hampshire 03054 US
HANSEN, Hans
18 Sanborn Avenue Apartment 3 Somerville, Massachusetts 02143 US
MACKEY, Matthew
52 Henry Avenue Melrose, Massachusetts 02176 US
SCHILLER, Shawn
614 Hilldale Avenue Haverhill, Massachusetts 01832 US
OGAWA, Chikako
Lichtstrasse 35 CH-4056 Basel CH
DAVIS, Heather
202 Morgan Drive Haverhill, Massachusetts 01832 US
ENDO, Atsushi
311 Lowell Street,Apartment 1123 Andover, MA 01810 US
ISHIZAKA, Sally
110 Mountvale Road Weston, MA 02493 US

Fullmektig info chevron_right

Fullmektig i Norge:
ZACCO NORWAY AS
Postboks 488 0213 OSLO NO ( OSLO kommune, Oslo fylke )

Org.nummer: 982702887
Din referanse: V8877NO00
  • Foretaksnavn:
  • Foretaksform:
  • Næring:
  • Forretningsadresse:
     

Kilde: Brønnøysundregistrene
Fullmektig i EP:
Stansfield, Kevin
Eisai Europe Limited Legal - IP Department European Knowledge Centre Mosquito Way Hatfield, Herts AL10 9SN GB

Prioritet info chevron_right

2013.10.14, US 201361890718 P

Anførte dokumenter info chevron_right

WO-A2-2005/007672 (B1)

COSTEDOAT-CHALUMEAU N ET AL: "Why all systemic lupus erythematosus patients should be given hydroxychloroquine treatment?", JOINT BONE SPINE, ELSEVIER, PARIS, FR, vol. 77, no. 1, 1 January 2010 (2010-01-01), pages 4-5, XP026832816, ISSN: 1297-319X [retrieved on 2010-01-01] (B1)

Sakshistorikk info chevron_right

Statushistorie

Liste over statusendringer i sakshistorikk
Hovedstatus Beslutningsdato, detaljstatus
EP patent gjort gjeldende i Norge EP patent besluttet gjeldende i Norge
EP under behandling Forespørsel om å gjøre EP patent gyldig er mottatt

Korrespondanse

expand_more file_download  
Liste over sakshistorikk og korrespondanse
Dato Type korrespondanse Journal beskrivelse
Innkommende EP Publiseringsdokument fra EPO
09-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Innkommende EP Publiseringsdokument fra EPO
08-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Innkommende EP Publiseringsdokument fra EPO
07-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Innkommende EP Publiseringsdokument fra EPO
06-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Utgående EP Varsel om betaling av første årsavgift (3319) (PTEP3057964)
05-01 Via Altinn-sending EP Varsel om betaling av første årsavgift (3319) (PTEP3057964)
Innkommende EP Publiseringsdokument fra EPO
04-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Utgående EP Registreringsbrev (3210) (PTEP3057964)
03-01 Brev UT EP Registreringsbrev (3210) (PTEP3057964)
Innkommende, AR360388849 Søknadsskjema Patent
01-01 Søknadsskjema Patent Søknadsskjema Patent
01-02 Fullmakt Fullmakt
01-03 EP oversettelse EP krav
Innkommende EP Publiseringsdokument fra EPO
02-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Informasjon om ikke tilgjengelige dokumenter

Betaling info chevron_right

Til betaling:

Neste fornyelse/årsavgift:

Betalingshistorikk:

Liste av betalinger
Beskrivelse / Fakturanummer Betalingsdato Beløp Betaler Status
Årsavgift 11. avg. år (EP) 2024.10.29 4550 COMPUTER PACKAGES INC. Betalt og godkjent
Årsavgift 10. avg. år (EP) 2023.10.27 3200 COMPUTER PACKAGES INC. Betalt og godkjent
Årsavgift 9. avg. år (EP) 2022.10.27 2850 COMPUTER PACKAGES INC. Betalt og godkjent
Årsavgift 8. avg. år (EP) 2021.10.28 2550 COMPUTER PACKAGES INC. Betalt og godkjent
Årsavgift 7. avg. år (EP) 2020.10.28 2200 COMPUTER PACKAGES INC. Betalt og godkjent
32002557 expand_more 2020.03.11 5500 TANDBERG INNOVATION AS Betalt
Denne oversikten kan mangle informasjon, spesielt for eldre saker, om tilbakebetaling, internasjonale varemerker og internasjonale design.

Publikasjon(er) info chevron_right

Lenker til publikasjoner og Norsk Patenttidende (søkbare tekstdokumenter)

Oversettelse av europeisk patentskrift
Allment tilgjengelig patentsøknad
Norsk Patenttidende - ved meddelelse
Nye digitale Norske Tidende, nyhet om tjenesten ved lansering
Om Norske Tidende
Hva betyr A1, B, B1, C osv? info
Kapitler uten data er fjernet. Melding opprettet: 28.04.2025 07:33:23